Qube Research & Technologies LTD Bio Line Rx Ltd. Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 11,935 shares of BLRX stock, worth $39,982. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,935
Previous 13,035
8.44%
Holding current value
$39,982
Previous $7,000
71.43%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding BLRX
# of Institutions
36Shares Held
2.83MCall Options Held
75.1KPut Options Held
5.1K-
Highbridge Capital Management LLC New York, NY1.01MShares$3.38 Million0.05% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.73 Million4.05% of portfolio
-
Values First Advisors, Inc.166KShares$557,6040.02% of portfolio
-
Atria Wealth Solutions, Inc. New York, NY94.1KShares$315,3450.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC92KShares$308,2000.0% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $206M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...